Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2016-12-27 Major Shareholding Noti…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Pharmena_27_12_16 Zawiadomienie: zmiana stanu posiadania
Major Shareholding Notification Classification · 99% confidence The document text is a formal notification dated 27.12.2016 regarding a change in the total number of votes held by Pelion S.A. in Pharmena S.A. It explicitly details the acquisition of 607,512 shares on December 22, 2016, and calculates the resulting change in shareholding percentage (from 50.09% to 57.00% when including subsidiaries). This type of filing, which reports changes in significant share ownership thresholds due to transactions, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and specific, focusing only on the ownership change, not a full annual report (10-K) or an earnings release (ER).
2016-12-27 Polish
Ujawnienie stanu posiadania – zwiększenie przez akcjonariusza udziału w ogólnej liczby głosów. - Content (PL)
Major Shareholding Notification Classification · 95% confidence The document text is very short (592 characters) and explicitly states that the content of a notification regarding a change in the total number of votes held by Pelion S.A. (a shareholder) is attached as an appendix ('Treść zawiadomienia stanowi załącznik do niniejszego raportu.'). This structure—a brief announcement referencing an attached/enclosed document detailing a change in significant shareholding—strongly suggests a notification of a change in major share ownership crossing a threshold. This aligns best with the Major Shareholding Notification (MRQ) definition. Although it is a regulatory filing under Polish law (art. 70 pkt. 1), MRQ is the most specific category available for this content type.
2016-12-27 Polish
Pelion_Pharmena_27_12_16_zawiadomienie nabycia akcji
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). It details the acquisition ('Nabycie') of shares ('akcje') by a person closely associated with management board members of Pharmena S.A. This structure, focusing on personal share transactions by directors/executives under MAR (Market Abuse Regulation) reporting requirements, directly corresponds to the definition of Director's Dealing.
2016-12-27 Polish
Informacja o transakcjach wykonywanych przez osoby pełniące obowiązki zarządcze - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (563 characters) and appears to be a regulatory notification written in Polish. It explicitly references Article 19(3) of Regulation (EU) No 596/2014 (MAR regulation), which pertains to transactions by persons discharging managerial responsibilities (PDMRs) or persons closely associated with them. The text states that the Management Board received a notification regarding the acquisition of company shares by an associated person (Pelion S.A.) of two Supervisory Board members. This type of insider transaction disclosure is specifically covered by the 'Director's Dealing' category (DIRS). Although it mentions the content is an attachment, the primary nature of the filing is the disclosure of the transaction itself, which aligns best with DIRS, rather than a general RPA or RNS, as DIRS is a specific category for insider trades.
2016-12-27 Polish
Zakończenie oceny formalnej wniosku o autoryzację 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a current report (raport bieżący) from PHARMENA S.A. informing about the status of the authorization process for a new food ingredient (1-MNA) by the European Food Safety Authority (EFSA). It discusses regulatory steps, timelines (until April 30, 2017), and the potential impact on company revenue. This type of communication, detailing regulatory progress on a product or legal matter, fits best under 'Legal Proceedings Report' (LTR) if it relates to regulatory hurdles, or 'Regulatory Filings' (RNS) as a general update. Given the focus on the formal authorization process by a regulatory body (EFSA) and the potential market impact, it is a specific regulatory update. Since there is no specific code for 'Regulatory Approval Update', and it is not an earnings release (ER), management discussion (MDA), or a formal legal proceeding (LTR), the most appropriate general category for significant, non-financial, regulatory news is 'Regulatory Filings' (RNS). The document length is short (2068 chars), but it contains substantive information rather than just announcing another report, so RPA is less likely than RNS.
2016-11-14 Polish
Przekazanie do EFSA uzupełnienia dokumentacji dot. wniosku o autoryzację 1-MNA jako nowego składnika żywności - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a current report (raport bieżący) from PHARMENA S.A. informing about sending supplementary documentation to the European Food Safety Authority (EFSA) regarding the authorization of 1-MNA as a novel food ingredient. It discusses regulatory processes (Regulation 258/97), potential market impact, and future steps. This content relates to regulatory submissions, legal/regulatory processes concerning a product, and its potential market entry. It is not a standard financial report (10-K, IR, ER), a management change announcement (MANG), or a director's dealing (DIRS). Since it specifically details an update on a regulatory submission process that could significantly impact revenue, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Legal Proceedings Report' (LTR) if viewed as a regulatory action, but RNS is the broader, safer fallback for non-standard regulatory updates that aren't explicitly about litigation or standard financial reporting. Given the context of submitting documentation for authorization, RNS is the most appropriate general regulatory filing category.
2016-10-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.